Entasis Antibiotic Indication Changed Ahead Of FDA Panel, Ending Quest For First Pathogen-Specific Approval

 
• By Sarah Karlin-Smith

Entasis’s sulbactam-durlobactam gets solid review from FDA ahead of its 17 April advisory committee meeting, but the company looks like it will have to settle for a narrower indication than it initially proposed.

lungs
FDA’s Antimicrobial Drugs Advisory committee will vote on Entasis’ antibiotic for two types of pneumonia 17 April. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers